Trading was heavy with 3,778K shares changing hands on Tuesday. Volume was up 284.38% over the stocks average daily volume.
Traders are more bullish on the company if you take a look at the change in short interest. The company realized a fall in short interest of -35.79% as of October 13, 2017 from the last reporting period. Short shares fell 574,815 over that period. Days to cover increased 1.0 to 1.0 and the percentage of shorted shares was 0.07% on October 13.
Here are a few substantial investment firms who have updated their positions. As of quarter end Vanguard Group Inc had sold a total of 10,381 shares trimming its stake by 84.5%. The value of the company’s investment in Itus Corp Cmn went from $36,000 to $2,000 decreasing 94.4% quarter to quarter. Ubs Group Ag grew its ownership by buying 1,118 shares an increase of 102.9% as of 06/30/2017. Ubs Group Ag now holds 2,204 shares valued at $3,000. The total value of its holdings decreased 0.0%.
The company is down from yesterday’s close of 2.63. The P/E ratio is currently N/A and market cap is 38.45M. As of the latest earnings report the EPS was $-0.64 with 15.32M shares now outstanding.
ITUS Corporation, launched on November 5, 1982, is involved in developing a diagnostic platform called Cchek, for the early detection of tumor-based cancers. The Cchek cancer detection platform measures a patient’s immune response to a malignancy by detecting the presence, absence and quantity of certain immune cells that exist in and around a tumor and that enter the blood stream. Instead of seeking to alter or boost the body’s immune system and its ability to destroy cancer cells, the Company has developed techniques and protocols for measuring the subtle immunological changes that occur in the blood stream during tumor development. Through its protocols, the Company has detected the biomarkers in the peripheral blood of biopsy verified cancer patients, and in distinguishing the blood of healthy patients from the blood of cancer patients..